NetworkNewsBreaks – Lexaria Bioscience Corp. (CS

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Reports Positive Topline Results from DehydraTECH™ Absorption Study

Drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced positive topline results following the completion of its first ingestible nicotine in vivo absorption study. The company is pursuing the use of its patented DehydraTECH™ technology as a new nicotine delivery method. The delivery method, in the form of an edible dose absorbed through the gastrointestinal tract, could potentially serve as a nicotine replacement therapy or as an alternative product format for regular tobacco users. Among other highlights, DehydraTECH™ demonstrated major nicotine absorption performance improvements including 1,160% faster delivery of equivalent peak quantities of nicotine to the bloodstream than achieved with controls as well as a 148% gain in the quantity of peak nicotine delivery to the bloodstream compared to controls. “This data supports further investigation of the many possible benefits of our DehydraTECH™ technology for nicotine delivery with potential both as a nicotine replacement therapy as well as an alternative product format for regular tobacco users over today’s inhaled options,” Lexaria president John Docherty stated in the news release.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer